(Q44314310)

English

Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients

scientific article published on 15 June 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

phase II clinical trial

0 references

6

object named as

Laura Rosiñol

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

author name string

Teresa Caballero-Velázquez

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Lucia López-Corral

2

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Cristina Encinas

3

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Cristina Castilla-Llorente

4

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Rodrigo Martino

5

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Antonia Sampol

7

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Dolores Caballero

8

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

David Serrano

9

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Inmaculada Heras

10

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Jesús San Miguel

11

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

José A Pérez-Simón

12

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

language of work or name

0 references

publication date

15 June 2013

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

162

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

474-482

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Recent major improvement in long-term survival of younger patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

A comparison of allografting with autografting for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

The changing landscape of myeloma therapy

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Progress in allogeneic transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12410

21 January 2018

Identifiers

10.1111/BJH.12410

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

release_bwmxr4pbarh3pppeyni624ta3q

1 reference

https://api.fatcat.wiki/v0/release/bwmxr4pbarh3pppeyni624ta3q

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44314310&oldid=2126247664"